These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 22264265)

  • 21. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients.
    Ning Y; Zhang W; Hanna DL; Yang D; Okazaki S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; El-Khoueiry A; Lenz HJ
    Pharmacogenomics J; 2018 Jan; 18(1):29-34. PubMed ID: 27503579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A; Gao H; Anfossi S; Cohen E; Mego M; Lee BN; Tin S; De Laurentiis M; Parker CA; Alvarez RH; Valero V; Ueno NT; De Placido S; Mani SA; Esteva FJ; Cristofanilli M; Reuben JM
    Mol Cancer Ther; 2012 Nov; 11(11):2526-34. PubMed ID: 22973057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Significance of
    Strati A; Nikolaou M; Georgoulias V; Lianidou ES
    Cells; 2019 Jun; 8(7):. PubMed ID: 31261917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells.
    Bidard FC; Vincent-Salomon A; Sigal-Zafrani B; Diéras V; Mathiot C; Mignot L; Thiery JP; Sastre-Garau X; Pierga JY
    Ann Oncol; 2008 Mar; 19(3):496-500. PubMed ID: 18187488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
    Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
    Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer.
    Banys M; Krawczyk N; Becker S; Jakubowska J; Staebler A; Wallwiener D; Fehm T; Rothmund R
    Breast Cancer Res Treat; 2012 Feb; 132(1):121-9. PubMed ID: 21562707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
    Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
    PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
    Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study.
    Hinz S; Hendricks A; Wittig A; Schafmayer C; Tepel J; Kalthoff H; Becker T; Röder C
    BMC Cancer; 2017 Jan; 17(1):53. PubMed ID: 28086834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients.
    Schindlbeck C; Andergassen U; Hofmann S; Jückstock J; Jeschke U; Sommer H; Friese K; Janni W; Rack B
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1055-62. PubMed ID: 23525580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
    Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
    Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
    Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
    Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
    Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
    Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.